SZSourour Zina

Sourour Zina

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sourour Zina has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Hager Ben Amor

    Department of Ophthalmology, Fattouma Bourguiba University Hospital, Faculty of Medicine, University of Monastir, Monastir, Tunisia

    2 shared publications
  • Sana Khochtali

    Department of Ophthalmology, Fattouma Bourguiba University Hospital, Faculty of Medicine, University of Monastir, Monastir, Tunisia

    2 shared publications
  • Chiraz Abdelhedi

    Department of Ophthalmology, Fattouma Bourguiba University Hospital, Faculty of Medicine, University of Monastir, Monastir, Tunisia

    1 shared publication
  • Imen Ksiaa

    Department of Ophthalmology, Fattouma Bourguiba University Hospital, Faculty of Medicine, University of Monastir, Monastir, Tunisia

    1 shared publication
  • Imen Ksiaa

    Department of Ophthalmology, Fattouma Bourguiba University Hospital, Faculty of Medicine, University of Monastir, Monastir, Tunisia

    1 shared publication
  • Melek Kechida

    Department of Internal Medicine and Endocrinology, Fattouma Bourguiba University Hospital, Faculty of Medicine of Monastir, University of Monastir, Monastir, Tunisia

    1 shared publication

Latest Publications

  • Multimodal imaging in IRVAN syndrome presenting with Branch Retinal Artery Occlusion

    by Sourour Zina, Imen Ksiaa, Chiraz Abdelhedi, Hager Ben Amor, Sonia Attia, Sana Khochtali, Moncef Khairallah

    Purpose: To describe multimodal imaging findings in a patient with idiopathic retinal vasculitis, aneurysms, and neuroretinitis (IRVAN) syndrome presenting with branch retinal artery occlusion (BRAO). Case description: A 33-year-old woman presented with acute BRAO in the right eye. A diagnosis of underlying IRVAN syndrome was made based on the presence of arteriolar aneurysms on the optic disc and along major arterioles and faint retinal hard exudates in both eyes. Eight months later, best-corrected visual acuity was 20/25 in the right eye and 20/20 in the left eye. The hard exudates had increased, and there were extensive areas of peripheral retinal capillary nonperfusion without new vessels. Optical coherence tomography (OCT) showed a localized retinal thinning corresponding to the prior BRAO. Fundus autofluorescence showed nodulo-linear periarterial hypoautofluorescence. OCT angiography (OCTA) showed localized ischemic changes, mainly involving the deep capillary plexus, corresponding to the area of resolved BRAO. It also clearly delineated the optic disc aneurysms. The patient received bilateral scatter laser photocoagulation directed to areas of peripheral capillary nonperfusion. Over a 6-month follow-up period, visual acuity remained unchanged, and there was no evidence of disease progression. Conclusion: Multimodal imaging, including fundus autofluorescence, OCT, and OCTA can provide additional valuable information in the evaluation of IRVAN syndrome complicated with BRAO.


  • Diagnosing retinal vasculitis and its implications for treatment

    by Nesrine Abroug, Sourour Zina, Molka Khairallah, Imen Ksiaa, Melek Kechida, Hager Ben Amor, Sana Khochtali, Moncef Khairallah

    Introduction: Retinal vasculitis (RV) is a sight-threatening intraocular inflammatory condition involving retinal blood vessels. Discrimination between infectious and noninfectious etiologies is mandatory to appropriate management and favorable outcome. Areas covered: A comprehensive literature review between January 1986 and January 2019 was conducted in PubMed database. Pathophysiology, clinical and imaging features, differential diagnosis, treatment, and prognosis of RV were reviewed. Expert opinion: In any patient with RV, a tailored diagnostic approach is recommended. A masquerade syndrome should always be excluded first, and then an infectious cause must be ruled out before corticosteroid or immunosuppressive therapy can be considered. Clinician also should be aware of sight-threatening complications that may affect visual prognosis.